Compare GLUE & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLUE | LQDT |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 985.8M |
| IPO Year | 2021 | 2005 |
| Metric | GLUE | LQDT |
|---|---|---|
| Price | $17.47 | $32.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $32.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.0M | 125.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.10 |
| EPS | N/A | ★ 0.23 |
| Revenue | $123,672,000.00 | ★ $476,669,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | ★ $72.42 | $139.30 |
| Revenue Growth | ★ 63.54 | 31.20 |
| 52 Week Low | $3.76 | $21.67 |
| 52 Week High | $25.77 | $33.61 |
| Indicator | GLUE | LQDT |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 62.12 |
| Support Level | $17.36 | $30.51 |
| Resistance Level | $18.15 | $32.58 |
| Average True Range (ATR) | 0.94 | 0.82 |
| MACD | 0.32 | 0.33 |
| Stochastic Oscillator | 88.92 | 85.44 |
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.